BillionToOne

BillionToOne Capital Expenditures

The Capital Expenditures (CapEx) of BillionToOne (BLLN) as of Nov 17, 2026 is -8.88 M USD. In the previous year, Capital Expenditures (CapEx) was -5.40 M USD — a change of 64.40% (lower).

Capital Expenditures

-8.88 MUSD

YoY

64.40%

Last updated:

Capital Expenditures (CapEx) of BillionToOne is 2025 -8.88 M USD. Capital Expenditures (CapEx) of BillionToOne was 2024 -5.40 M USD. It decreases by 64.40% lower compared to the previous year.

The BillionToOne Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2023
-6.17 M USD
Jan 1, 2024
-5.40 M USD
Jan 1, 2025
-8.88 M USD
The BillionToOne Capital Expenditures history
YEARCapital ExpendituresYoY
-8.88 MUSD+64.40%
-5.40 MUSD-12.50%
-6.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BillionToOne Stock analysis

What does BillionToOne do? BillionToOne Inc generates revenue through its Quantitative Counting Template (QCT) molecular counter platform, the only technology capable of counting DNA molecules at the single-count level. The company's product UNITY offers noninvasive prenatal screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA) using maternal blood samples. Healthcare providers and genetic testing laboratories purchase the QCT platform and UNITY services to detect genetic disease risks early. The primary customer segments include hospitals, clinics specializing in obstetrics and genetics, and diagnostic laboratories seeking advanced molecular diagnostics solutions. UNITY is marketed as a single-sample test for fetal cell-free DNA analysis, targeting prenatal care providers who require precise genetic risk assessment. The QCT platform is sold to laboratories needing high-precision DNA counting capabilities for research and clinical applications. These services are utilized by healthcare facilities focused on maternal-fetal health and genetic disorder screening. The company's revenue streams are derived from licensing the QCT platform to diagnostic institutions and providing the UNITY screening service directly to healthcare providers. No additional products or services are mentioned in the business description beyond these two offerings. BillionToOne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BillionToOne stock

Capital Expenditures (CapEx) of BillionToOne is -8.88 M USD in 2025.

Capital Expenditures (CapEx) of BillionToOne changed from -5.40 M USD to -8.88 M USD, representing a 64.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) BillionToOne since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s BillionToOne historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BillionToOne

All Key Metrics — BillionToOne